Abl: The prototype of oncogenic fusion proteins

Cellular and Molecular Life Sciences

Volumn 61, Issue 23, 2004, Pages 2897-2911

  Saglio, G ^a   Cilloni, D ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

BCR ABL; c Abl; CML; Ph chromosome; Tyrosine kinase

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; PAXILLIN; PROTEIN TYROSINE KINASE;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; BLAST CELL CRISIS; BONE MARROW; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; CELL ADHESION; CELL CYCLE G1 PHASE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; LIFE EXPECTANCY; LYMPHOMA; MITOGENESIS; MOLECULAR DYNAMICS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTO ONCOGENE; RADIATION EXPOSURE; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; STROMA;

APOPTOSIS; BONE MARROW CELLS; CELL ADHESION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EXONS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASMS; PHILADELPHIA CHROMOSOME; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSLOCATION, GENETIC;

EID: 12144273864     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4271-0     Document Type: Review

References (145)

1. Robinson D. R., Wu Y. M. and Lin S. F. (2000) The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557
2. Geary C. G. (2000) The story of chronic myeloid leukaemia. Br. J. Haematol. 110: 2-11
3. Goldman J. M, Melo J. V. (2003) Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 349: 1451-1464
4. Nowell P. C. and Hungerford D. A. (1960) A minute chromosome in human chronic granulocitic leukemia. Science 32: 1497-1501
5. Rowley J. D. (1973) A novel consistent chromosome abnormality in chronic myelogenous leukemia detected by quinacrine fluorescence and Giemsa staining. Nature 243: 290-203
6. Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R. and Grosveld G. (1984) Philadelphia chromosome breakpoint are clustered within a limited region, bcr, on chromosome 22. Cell 33: 93-99
7. Heisterkamp N, Stam K., Groffen J., de Klein A. and Grosveld G. (1985) Structural organization of the bcr gene and its role in the Ph translocation. Nature 315: 758-761
8. Ben-Neriah Y., Daley G. Q., Mes-Masson A. M, Witte O. N. and Baltimore D. (1986) The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 233: 212-214
9. Melo J. V. (1996) The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 88: 2375-2384
10. Saglio G., Pane F., Martinelli G. and Guerrasio A. (1997) BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. Leuk. Lymphoma 26: 281-286
11. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B. J. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1): 100-104
12. Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2(5): 561-566
13. Abelson H. T. and Rabstein E. S. (1970) Cancer Res. 30: 2213-2222
14. Pendergast A. M. (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85: 51-100
15. Tybulewicz. V. L. J., Crawford C. E., Jackson P. K., Bronson R. T. and Mulligan R. C. (1991) Neonatal lethality and lymphopenia in micewith a homozygous disruption of the c- abl proto-oncogene. Cell 65: 1153-1163
16. Welch P. J. and Wang J. Y. (1993) A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75: 779-790
17. Baskaran R., Wood L. D., Whitaker L. L., Canman C. E., Morgan S. E., Xu Y. et al. (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387: 516-519
18. Plattner R., Kadlec L., DeMali K. A., Kazlauskas A. and Pendergast A. M. (1999) c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13: 2400-2411
19. Furstoss O., Dorey K., Simon V, Barila D., Superti-Furga G. and Roche S. (2002) c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 21(4): 514-524
20. Plattner R., Irvin B. J., Guo S., Blackburn K., Kazlauskas A., Abraham R. T. et al. (2003) A new link between the c-Abl tyrosine kinase and phosphoinositide signaling through PLC-gamma1. Nat. Cell Biol. 5(4): 309-319
21. Rebecchi M. J. and Pentyala, S. N. (2000) Structure, function and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80: 1291-1335
22. Plattner R., Koleske A. J., Kazlauskas A. and Pendergast A. M. (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol. Cell Biol. 24(6): 2573-2583
23. Sawyers C. L., McLaughlin J., Goga A., Havlik M. and Witte O. (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell. 77(1): 121-131
24. Wang J. (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643-5650
25. Barila D., Mangano R., Gonfloni S., Kretzschmar J., Moro M., Bohmann D. et al. (2000) A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. EMBO J. 19: 273-281
26. Scheijen B. and Griffin J. D. (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21: 3314-3333
27. Puil L., Liu J., Gish G., Mbamalu G., Bowtell D., Pelicci P. G. et al. (1994). BCR-ABL oncoproteins bind directly to activators of Ras signalling pathway. EMBO J. 13: 764-773
28. Raitano A. B., Halpern J. R., Hambuch T. M. and Sawyers C. L. (1995) Proc. Natl. Acad. Sci. USA 92: 11746-11750
29. McWhirter J. R. and Wang J. Y. J. (1993) An actin-binding function contributes to transformation by the Bcr-Abl onncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 12: 1533-1546
30. Schwartzberg P. L., Stall A. M., Hardin J. D., Bowdish K. S., Humaran T., Boast S. et al. (1991) Mice homozygous for ABL m1 mutation shows poor viability and depletion of selected B and T population. Cell 65: 1165-1176
31. Woodring P. J., Hunter T. and Wang J. Y. (2003) Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J. Cell. Sci. 116: 2613-2626
32. Kain K. and Klemke R. (2001) Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J. Biol. Chem. 276: 16185-16192
33. Wen S. T., Jackson P. K. and Van Etten R. A. (1996) EMBO J., 15: 1583-1595
34. Taagepera S., McDonald D., Loeb J. E., Whitaker L. L., MacLeod A. K, Wang J. Y. J. et al. (1998) Proc. Natl. Acad. Sci. USA 95: 7457-7462
35. Preston D. L., Kusumi S., Tomonaga M., Izumi S., Ron E., Kuramoto A. et al. (1994) Cancer incidence in atomic bomb survivors. III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat. Res. 137: Suppl: S68-97
36. Deininger M. W., Bose S., Gora-Tybor J., Yan X. H., Goldman J. M. and Melo J. V. (1998) Selective inductio of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 58: 421-425
37. Biernaux C., Loos M., Sels A., Huez G. and Stryckmans P. (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86: 3118-3122
38. Neves H., Ramos C., da Silva M. G., Parreira A. and Parreira L. (1999) The nuclear topography of ABL, BCR, PML and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood 93: 1197-1207
39. Saglio G., Storlazzi C. T., Giugliano E., Surace C., Anelli L., Rege-Cambrin G. et al. (2002) A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. Proc. Natl. Acad. Sci. USA 99(15): 9882-9887
40. JiY., Eichler E. E., Schwartz S. and Nicholls R. D. (2000) Structure of chromosomal duplicons and their role in mediating human genomic disorders. Genome Res. 10: 597-610
41. Johansson B., Fioretos T. and Mitelman F. (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 107: 76-94
42. Chissoe S. L., Bodenteich A., Wang Y. F., Wang Y. P., Burian D., Clifton S. W. et al. (1995) Sequence and analysis of the human ABE gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27: 67-82
43. Shtivelman E., Lifshitz B., Gale R. P., Roe B. A. and Canaani E. (1985) Fused transcript of abl and bcr genes in chronic myeloid leukaemia. Nature 315(6020): 550-554
44. nd edn, Wiley-Liss, New York.
45. Chan L. C., Karhi K. K., Rayter S. I., Heisterkamp N., Eridani S., Powles R. et al. (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325: 635-637
46. Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R. P., Dreazen O. et al. (1987) A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 330: 386-388
47. Lugo T. G., Pendergast A. M., Muller A. J. and Witte O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247(4946): 1079-1082
48. Melo J. V., Myint H., Galton D. A. and Goldman J. M. (1994) p190 BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 8(1): 208-211
49. Saglio G., Pane F., Gottardi E., Frigeri F., Buonaiuto M. R., Guerrasio A. et al. (1996) Consistent amounts of acute leukemia associated p 190 bcr/abl transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 87(3): 1075-1080
50. Saglio G., Guerrasio A., Rosso C., Zaccaria A., Tassinari A., Serra A. et al. (1990) New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 76(9): 1819-1824
51. Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R. et al. (1996) Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88(7): 2410-2414
52. Daley G. Q., Van Etten R. A. and Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830
53. Pluk H., Dorey K. and Superti-Furga G. (2002) Autoinhibition of c-Abl. Cell 108: 247-254
54. McWhirter J. R., Galasso D. L. and Wang J. Y. (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13: 7587-7595
55. Pendergast A. M., Quilliam L. A., Cripe L. D., Bassing C. H., Dai Z., Li N. et al. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 75(1): 175-185
56. Hantschel O. and Superti-Furga G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell. Biol. 5(1): 33-44
57. Wen S. T. and Van Etten R. A. (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11: 2456-2467
58. Shi, Y., Alin K. and Goff S. P. ( 1995) Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 9: 2583-2597
59. Dai Z., Pendergast A. M. (1995) Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9: 2569-2582
60. Hantschel O., Young M. A., Scheffzek K., Veach D., Bornmann W., Clarkson B. et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112(6): 859-871
61. Brasher B. B. and Van Etten R. A. (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275: 35631-35637
62. Dorey K., Engen J. R., Kretzschmar J., Wilm M., Neubauer G., Schindler T. et al. (2001) Phosphorylation and structure-based functional studies reveal a positive and a negative role for then activation loop of the c-Abl tyrosine kinase. Oncogene 20: 8075-8084
63. Dai Z., Quackenbush R. C., Courtney K. D., Grove M., Cortez D., Reuther G. W. et al. (1998) Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12(10): 1415-1424
64. Brasher B. B., Roumiantsev S. and Van Etten R. A. (2001) Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene 20(53): 7744-7752
65. Tiribelli M., Tonso A., Ferro D., Parziale A., Cambrin G. R., Scaravaglio P. et al. (2000). Lack of SH3 domain does not imply a more severe clinical course in Ph+ chronic myeloid leukemia patients. Blood. 95(12): 4019-4020
66. Golub T. R., Goga A., Barker G. F., Afar D. E., McLaughlin J., Bohlander S. K. et al. (1996) Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 016(8): 4107-4116
67. Okuda K., Golub T. R., Gilliland D. G. and Griffin J. D. (1996) p210BCR/ABL, p190BCR/ABL and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13(6): 1147-1152
68. Cortez D., Reuther G. W and Pendergast A. M. (1997) The BCR-ABL tyrosine kinase activates mitotic signaling pathways and stimulates Gl-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342
69. Pelicci G., Lanfrancone L., Salcini A. E., Romano A., Mele S., Grazia Borrello M. et al. (1995) Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 11(5): 899-907
70. Oda T., Heaney C., Hagopian J. R., Okuda K., Griffin J. D. and Druker B. J. (1994) Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269(37): 22925-22928
71. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M. A., Pisick E. et al. (1996) The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol- 3′ kinase pathway. Oncogene 12(4): 839-846
72. Salgia R., Pisick E., Sattler M., Li J. L., Uemura N., Wong W. K. et al. (1996) p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J. Biol. Chem. 271(41): 25198-25203
73. Raitano A. B., Halpern J. R., Hambuch T. M. and Sawyers C. L. (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92: 11746-11750
74. Sawyers C. L., McLaughlin J. and Witte O. N. (1995) Genetic requirement for RAS in the trasformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene. J. Exp. Med. 181: 307-313
75. Greenberger J. S. (1989) Ras mutations in human leukemia and related disorders. Int. J. Cell Cloning 7(6): 343-359
76. Gaidano G. L., Guerrasio A., Serra A., Carozzi F., Rege-Cambrin G., Petroni D. et al. (1993) Mutations in the p53 and RAS family genes are associated with tumor progression of BCR-ABL negative chronic myeloproliferative disorders. Leukemia 7: 946-953
77. Zou X., Rudchenko S., Wong K. and Calame K. (1997) Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1 and cyclin-dependent kinases. Genes Dev. 11(5): 654-662
78. Kirchnera D., Duysterc J., Ottmannd O., Roland M. Schmidt L., Bergmanna D. et al. (2003) Mechanisms of Bcr-Abl-mediated NF-kB/Rel activation. Exp. Hematol. 31: 504-511
79. Ilaria R. L. Jr and Van Etten R. A. (1996) P210 and P190(BCR/ ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271: 31704-31710
80. Carlesso N., Frank D. A. and Griffin J. D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183(3): 811-820
81. Salgia R., Li J. L., Lo S. H., Brunkhorst B., Kansas G. S., Sobhany E. S. et al. (1995) Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J. Biol. Chem. 270(10): 5039-5047
82. Salgia R., Brunkhorst B., Pisick E., Li J. L., Lo S. H., Chen L. B. et al. (1995) Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11(6): 1149-1155
83. Bhatia R., McGlave P. B., Dewald G. W., Blazar B. R. and Verfaillie C. M. (1995) Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85(12): 3636-3645
84. Upadhyaya G., Guba S. C., Sih S. A., Feinberg A. P., Talpaz M., Kantarjian H. M. et al. (1991) Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J. Clin. Invest. 88: 2131-2136
85. Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M. and Greaves M. F. (1987) Altered adhesive interactions with marrow stroma of haemopoietic progenitor cells in chronic myeloid leukemia. Nature 328(6128): 342-344
86. Verfaille C. M., McCarthy J. B. and McGlave P. B. (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 90: 1232-1241
87. Verfaille C. M., Benis A., Iida J., McGlave P. B. and McCarthy J. B. (1994) Adhesion of committed human hematopoietic progenitors to synthetic peptides from the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin 41 and the CD44 adhesion receptors. Blood 84(6): 1802-1811
88. Verfaille C. M. (1997) Stem cells in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America 11: 1079-1114
89. Eaves A. C., Cashman J. D., Gaboury L. A., Kalousek D. K. and Eaves C. J. (1986) Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc. Natl. Acad. Sci. USA 83(14): 5306-5310
90. Vigneri P. and Wang J. Y. (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7: 228-234
91. Varticovski L., Daley G. Q., Jackson P., Baltimore D. and Cantley L. C. (1991) Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol. Cell. Biol. 11(2): 1107-1113
92. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M. A. and Pisick E. (1996) The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol- 3′ kinase pathway. Oncogene 12(24): 839-846
93. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J. et al. (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI 3-kinase and PKB. Nature 385: 544-548
94. Sattler M., Mohi M. G., Pride Y. B., Quinnan L. R., Malouf N. A., Podar K. et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 1: 479-492
95. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J. K. et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16(20): 6151-6161
96. Jain S. K., Susa M., Keeler M. L., Carlesso N., Druker B. and Varticovski L. (1996) PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88(55): 1542-1550
97. Franke T. F., Kaplan D. R. and Cantley L. C. (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437
98. Fialkow P. J., Martin P. J., Najfeld V., Penfold G. K., Jacobson R. J. and Hansen J. A. (1981) Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 58: 158-163
99. O'Dwyer M. E., Gatter K. M., Loriaux M., Druker B. J., Olson SB, Magenis R. E. et al. (2003) Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17:481-487
100. Bumm T., Muller C., Al Ali H. K., Krohn K., Shepherd P., Schmidt E. et al. (2003) Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101: 1941-1949
101. Bernstein R. (1988) Cytogenetics of chronic myelogenous leukemia. Semin. Hematol. 25: 20
102. Ahuja H., Bar-Eli M., Arlin X., Advani S., Allen S. L., Goldman J. et al. (1991) The spectrum of molecular alterations in the evolution of chronic myelocitic leukemia. J. Clin. Invest. 87: 2042-2047
103. Gaidano G., Serra A., Guerrasio A., Rege-Cambrin G., Mazza U. and Saglio G. (1994) Genetic analysis of p53 and RB1 tumor suppression genes in blast crisis of chronic myeloid leukemia. Ann. Hematol. 68: 3-7
104. Serra A., Gottardi E., Della Ragione F., Saglio G. and Iolascon A. (1995) Involvement of cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukemia. Br. J. Haemat. 91: 625-629
105. Gaiger A., Henn T., Horth E., Geissler K., Mitterbauer G. and Maier-Dobersberger T. (1995) Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86(6): 2371-2378
106. Wada C., Shionoya S., Fujino Y., Tokuhiro H., Akahoshi T., Uchida T. et al. (1994) Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83: 3449-3456
107. Silly H., Chase A., Mills K. I., Apfelbeck U., Sormann S., Goldman J. M. et al. (1994) No evidence of microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukemia blast crisis. Leukemia 8: 1923-1928
108. Wadhwa J., Szydlo R. M., Apperley J. F., Chase A., Bua M., Marin D. et al. (2002) Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 99(7): 2304-2309
109. Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J. Natl. Cancer Inst. 89: 1616-1620
110. Gratwohl A., Hermans J., Niederwieser D., Frassoni F., Arcese W., Gahrton G. et al. (1993) Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation 12(5): 509-16
111. Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J. et al. (1990) Graft-versus-leukemia following bone marrow transplantation. Blood 75(3): 555-562
112. Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., Barrett A. J. and Goldman J. M. (1992) Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79: 1379-1381
113. Druker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037
114. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346: 645-652
115. O'Brien S. G., Guilhot F., Larson R. A., Gathmann I., Baccarani M., Cervantes F. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004
116. Druker B. J., Sawyers C. L., Kantarjian H., Resta D. J., Reese S. F., Ford J. M. et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042
117. Gambacorti-Passerini C. B., Gunby R. H., Piazza R., Galietta A., Rostagno R. and Scapozza L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4: 75-85
118. Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P. N. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 293: 876-880
119. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K. et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9): 3472-3475
120. Hochhaus A., Kreil S., Corbin A. S., La Rosee P., Muller M. C., Lahaye T. et al. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196
121. Shah N. P., Nicoll J. M., Nagar B., Gorre M. E., Paquette R. L., Kuriyan J. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125
122. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J. et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1): 276-283
123. Le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologna L., Cabrita G. et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95(5): 1758-1766
124. Gambacorti-Passerini C. B., Rossi F., Verga M., Ruchatz H., Gunby R., Frapolli R. et al. (2002) Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukaemic patients. Blood Cells Mol. Dis. 28(3): 361-372
125. Mahon F. X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F. and Reiffers J. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6): 2368-2373
126. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J. L., Philippe N., Facon T. et al. (2002) Several types of mutations of the Ab1 gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment. Blood 100(3): 1014-1018
127. Donato N. J., Wu J. Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B. B. et al. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64: 672-677
128. Ross D. M. and Hughes T. P. (2004) Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br. J. Cancer 90(1): 12-19
129. Hughes T. P., Morgan G. J., Martiat P. and Goldman J. M. (1991) Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77(4): 874-878
130. Guerrasio A., Martinelli G., Saglio G., Rosso C., Zaccaria A., Rosti G. et al. (1992) Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. Leukemia 6(6): 507-512
131. Hochhaus A., Lin F., Reiter A., Skladny H., Mason P. J., van Rhee F. et al. (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-a therapy by competitive polymerase chain reaction. Blood 87: 1549-1555
132. Cuneo A., Bigoni R., Emmanuel B., Smit E., Rigolin G. M., Roberti M. G. et al. (1998) Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 12: 1718-1723
133. Sinclair P. B., Nacheva E. P., Leversha M., Telford N., Chang J., Reid A. et al. (2000) Large deletions at the t(9;22) break-point are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95(3): 738-743
134. Cross N. C. P., Feng L., Chase A., Bungey J., Hughes T. P. and Goldman J. M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82: 1929-1936
135. Lion T., Henn T., Gaiger A., Kalhs P. and Gadner H. (1993) Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 341: 275-270
136. Lin F., van Rhee F., Goldman J. M. and Cross N. C. P. (1996) Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87: 4473-4478
137. van Rhee F., Lin F., Cullis J. O., Spencer A., Cross N. C. P., Chase A. et al. (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83: 3377-3783
138. Raanani P., Dazzi F., Sohal J., Szydlo R., van Rhee F., Reiter A. et al. (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br. J. Haematol. 99: 945-950
139. Emig M., Saussele S., Wittor H., Weisser A., Reiter A., Willer A. et al. (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13: 1825-1832
140. Beillard E., Pallisgaard N., van der Velden V. H. J., Bi W., Dee R., van der Scoot E. et al. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against Cancer Program. Leukemia 17(12): 2474-2486
141. Gabert J., Beillard E., van der Velden V. H. J., Bi W., Grimwade D., Pallisgaard N. et al. (2003) Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer Program. Leukemia 17(12): 2318-2357
142. Hughes T. P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M. L. et al. for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid Leukemia. N. Engl. J. Med. 349(15): 1423-1432
143. Rosti G., Martinelli G., Bassi S., Amabile M., Trabacchi E., Giannini B. et al. (2004) Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood 103(6): 2284-2290
144. Merx K., Muller M. C., Kreil S., Lahaye T., Paschka P., Schoch C. et al. (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon-a. Leukemia 16: 1579-1583
145. Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S. et al. (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17(12): 2401-2409